Skip to main content

Correction to: MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1)

The Original Article was published on 03 February 2016

Correction to: J Exp Clin Cancer Res 35, 25 (2016)

https://doi.org/10.1186/s13046-016-0300-8

Following publication of the original article [1], the authors identified minor errors in Figs. 6 and 7; specifically:

  • Fig. 6b: incorrect band used for MEKK1 band of MCF-7 cells; correct band is now used

  • Fig. 7a: incorrect band used for p38 band of MCF-7 cells; correct band is now used

The corrected figures are given here. The correction does not have any effect on the final conclusions of the paper.

Fig. 6
figure 1

The relative expressions of MEKK1mRNA and protein in MCF-7 and MCF-7/ADR cells after miRNA transfection. a qRT-PCR showing the mRNA expression of MEKK1 in MCF-7and MCF-7/ADR cells. b Western blot and densitometric analysis showing the protein expression of MEKK1 in MCF-7 cell and MCF-7/ADR cell. c The stability assay of MEKK1 mRNA. MCF-7/ADR cells were harvested at 0, 2, 4, 6 and 8 h after treatment with 5 mg/mL actinomycin D. Residual mRNAs was detected by qRT-PCR. All graphs show means ± S.D. of three independent experiments. (*P < 0.05 vs. NC;#P < 0.05 vs. Single)

Fig. 7
figure 2

Overexpression of miR-302 decreased the expression of the ERK signal pathway. a MCF-7 and MCF-7/ADR cells were transfected with miR-302a, miR-302b, miR-302c, miR-302d, miR-302S mimic, respectively. Total cellular proteins (50 μg) from exponentially growing cells treated as indicated in the figure were subjected to western blot analysis with antibodies directed against the proteins or their phosphorylated form as indicated. GAPDH was applied as control for equal loading. All experiments were carried three times independently. b Densitometric analysis for the detected protein expression

Reference

  1. Zhao L, Wang Y, Jiang L, et al. MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). J Exp Clin Cancer Res. 2016;35:25. https://doi.org/10.1186/s13046-016-0300-8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Minjie Wei.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhao, L., Wang, Y., Jiang, L. et al. Correction to: MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). J Exp Clin Cancer Res 41, 94 (2022). https://doi.org/10.1186/s13046-022-02312-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13046-022-02312-6